New Delhi, Sept. 8 -- Commercial refrigeration firm Trufrost & Butler, prebiotic soda brand Misfits, and medtech startup Dectrocel have secured funding in different funding rounds backed by private equity, venture capital, and angel investors.

Trufrost & Butler

Trufrost & Butler, a provider of commercial refrigeration and foodservice equipment, has raised $7 million (Rs 61 crore) in growth funding from private equity firm Carpediem Capital.

The company said the funds will be deployed to enhance order fulfilment, expand service infrastructure, ramp up domestic manufacturing, and explore select global markets.

Founded in 2018 by Neeraj Seth and Satish Dudeja, Trufrost & Butler partners with hotels, restaurants, and cafes. The company is expanding manufacturing and service capabilities to support domestic growth and entry into international markets.

Misfits

Misfits, a prebiotic soda brand, has secured an undisclosed amount in a seed round led by Nu Ventures, angel investor Subba Rao Telidevara, Turiya Advisory Services' managing partner Bijoy Daga, and investment consultant Robert Pancras.

The startup said the funding will be used to improve production capabilities, expand distribution, and fuel market penetration across India.

Founded by brothers Aditya and Yash Pai, Misfits offers prebiotic soda that contains zero added sugar and is low in calories.

Dectrocel

Health-tech startup Dectrocel has raised Rs 4 crore ($0.4 million) in a round led by IAN Group-backed BioAngels, with participation from PadUp Ventures and Vinners.

The round also saw participation from key investors from Indian Angel Network (IAN), including Nitin Zamre, Samir Kalia, and Mitesh Shah.

The startup said the funding will be used to scale commercial operations across India, enhance its self-learning AI model, expand into international markets, and accelerate the launch of upcoming AI tools in diagnostic modules.

Headquartered in Lucknow, Dectrocel develops AI-powered diagnostic solutions for respiratory and hepato-pancreatico-biliary (HPB) diseases. Its AI-based diagnostic tool DecXpert, approved for clinical use in India by the Central Drugs Standard Control Organisation (CDSCO), delivers chest X-ray and CT-scan interpretations.

Published by HT Digital Content Services with permission from VC Circle.